The Cure of Chronic Myeloid Leukemia: Are We There Yet?

Current Oncology Reports
Tapan Saikia

Abstract

A large number of chronic myeloid leukemia (CML) patients receiving tyrosine kinase inhibitors (TKIs) can now enjoy a deep molecular control of the disease and the life span could be approaching that of normal population. The purpose of the review is to evaluate current evidence and if we can talk of a cure. The revolution in the treatment of CML was apparent since the exquisite efficacy of imatinib mesylate, a tyrosine kinase inhibitor, was proven and received approval for newly diagnosed cases in 2001. Subsequent development of second-generation TKIs, nilotinib and dasatinib, has increased our armamentarium. These TKIs, because of their safety and efficacy, are now offered as first-line therapy, thus relegating use of allogeneic transplant to the second line or beyond. It has also been possible to stop TKIs in selected subsets in whom leukemia burden became undetectable and ~ 40% of them remain drug-free for a number of years-treatment-free remission (TFR). Nevertheless, much work needs to be done to eradicate leukemia stem cells as current TKIs appear unable to eradicate leukemia stem cells (LSC). Effective treatment of more advanced phase CML remains elusive. Further efforts to develop newer molecules targeting BCR-ABL and ...Continue Reading

References

Oct 1, 1991·British Journal of Haematology·M TalpazJ U Gutterman
Feb 1, 1986·Annals of Internal Medicine·E D ThomasK Doney
Apr 5, 2001·The New England Journal of Medicine·B J DrukerC L Sawyers
Jan 5, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F X MahonJ Reiffers
Mar 15, 2003·The New England Journal of Medicine·Stephen G O'BrienUNKNOWN IRIS Investigators
Aug 13, 2004·The New England Journal of Medicine·Catriona H M JamiesonIrving L Weissman
Dec 21, 2004·Cancer Cell·Catriona H M JamiesonEmmanuelle Passegué
Jul 1, 2005·Nature·Franziska MichorMartin A Nowak
Dec 8, 2006·The New England Journal of Medicine·Brian J DrukerUNKNOWN IRIS Investigators
Dec 23, 2008·International Journal of Hematology·Wing Y AuJianxiang Wang
Jun 8, 2010·The New England Journal of Medicine·Giuseppe SaglioUNKNOWN ENESTnd Investigators
Jun 8, 2010·The New England Journal of Medicine·Hagop KantarjianMichele Baccarani
Dec 24, 2010·The New England Journal of Medicine·Claude PreudhommeUNKNOWN France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC)
Sep 6, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jorge E CortesCarlo Gambacorti-Passerini
Dec 11, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philippe RousselotFrançois-Xavier Mahon
Feb 12, 2014·Indian Journal of Medical and Paediatric Oncology : Official Journal of Indian Society of Medical & Paediatric Oncology·Shweta BansalPurvish Parikh

❮ Previous
Next ❯

Citations

Feb 8, 2019·The Journal of Clinical Investigation·Simona StivalaSara C Meyer
Jun 7, 2019·Expert Opinion on Therapeutic Targets·Oscar M Tirado
Feb 6, 2020·Fundamental & Clinical Pharmacology·Higor de Oliveira RibeiroMarize Campos Valadares
Aug 3, 2021·Journal of Managed Care & Specialty Pharmacy·Rena M ContiSalvatore Salamone

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.